Actively Recruiting
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Led by Christoph Aufricht · Updated on 2023-12-08
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Nephrotic syndrome includes a group of kidney diseases causing protein loss in urine, blood protein abnormalities, fluid buildup, and kidney function problems. This research focuses on patients with resistant nephrotic syndrome, especially those with a condition called focal segmental glomerulosclerosis (FSGS), which can lead to kidney failure. The study aims to collect real-world data, connect patients and clinicians, recruit participants for future research, and build a biobank for studying biomarkers and disease progression. Participants who meet certain criteria, such as resistance to standard immunosuppressive treatments, specific protein levels in urine, and sufficient kidney function, will be invited to join the ARREST-NEPHROSIS registry. They will provide clinical information and samples to support research on resistant nephrotic syndrome. The registry supports long-term data collection to better understand treatment responses and disease outcomes. During the study, participants will undergo regular clinical assessments and contribute data about their health, treatments, and kidney function. Researchers will monitor proteinuria levels and kidney performance over time, including patient-reported outcomes. The study will last up to 20 years, allowing for continuous observation and networking among patients, families, and healthcare providers to improve future care and research opportunities.
CONDITIONS
Brief Title
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Resistant to standard immunosuppressive agents (if clinically indicated, e.g. primary/non-genetic forms)
- Persistent urinary protein-to-creatinine (UP/C) ratio greater than 1.0 g/g
- Estimated glomerular filtration rate (eGFR) greater than 30 ml/min per 1.73 m2
- Biopsy or a disease-causing genetic mutation associated with nephrotic syndrome
You will not qualify if you...
- Inability or unwillingness to comply with repeated assessments
- Objections against participation at discretion of the investigator
- Secondary nephrotic syndrome
- Patients with steroid-dependence or frequently relapsing disease (but achievement of complete remission)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 20 years
Participants who undergo routine care are observed with continuous prospective assessment of clinical and patient-reported outcomes, including proteinuria and kidney function.
Regular visits according to routine clinical practice; frequency varies by participant
Trial Site Locations
Total: 1 location
1
Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
Vienna, Austria, 1090
Actively Recruiting
Research Team
C
Christoph Aufricht, Prof. MD
L
Lisa Daniel-Fischer, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here